- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Xetra | 90,050 | 03.06.24 17:35:55 | +0,270 | +0,30% | 0,000 | 0,000 | 88,320 | 89,780 |
|
Regeneron Pharmaceuticals | 881535 | NASDAQ | 994,760 | 03.06.24 20:24:28 | +14,600 | +1,49% | 994,030 | 995,470 | 980,160 | 980,160 |
